Streetbeat News

Products Services

AGEN

Agenus has published a study in Cancer Discovery detailing the novel mechanism and effectiveness of its antibody, Botensilimab, in treatment-resistant cancers. The study highlights Botensilimab's increased activity across multiple cancers, its Fc-enhanced design for multifunctional immune activation, and its ability to remodel the tumor microenvironment. The antibody shows promise in treating over nine difficult-to-treat cancers, including microsatellite stable colorectal cancer.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 3:03 pm

ACTU

Actuate Therapeutics, Inc (NASDAQ:ACTU) is set to IPO on August 8, 2023, on the NASDAQ exchange. The company will offer shares priced between $8.00 and $10.00 each, with an insider lock-up period of 180 days ending on February 4, 2025. Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers.

Portfolio Pulse from Benzinga Insights

August 07, 2024 | 3:00 pm

SIGA

SPY

The WHO Chief announced that over 1 million polio vaccines will be sent to Gaza. Additionally, more than 50 confirmed and suspected Mpox cases have been reported in Burundi, Kenya, Rwanda, and Uganda. An emergency committee will assess the Mpox outbreak as a public health emergency, with the Clade 1B variant confirmed in Kenya, Rwanda, and Uganda.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 2:54 pm

UBER

Uber Technologies Inc. (NYSE:UBER) reported strong second-quarter financial results, surpassing market expectations with $10.7 billion in revenue and 47 cents earnings per share. The company saw significant growth in Latin America and the Asia Pacific regions and made strides in autonomous vehicle technology through partnerships with Waymo and Waabi. Following the positive results, Uber's stock rebounded by 10%, creating new support at $63.

Portfolio Pulse from Zaheer Anwari

August 07, 2024 | 2:28 pm

AYRWF

AYR Wellness Inc. reported a challenging Q2 2024 with a drop in revenue and gross profit, but remains optimistic about future growth, particularly in Ohio's cannabis market. The company saw a 16.6% YoY and 6.9% QoQ drop in gross profit, and a net loss of $39.3 million. Despite these setbacks, AYR launched recreational cannabis sales in Ohio and plans to improve its adjusted EBITDA margins in the second half of 2024.

Portfolio Pulse from Jelena Martinovic

August 07, 2024 | 2:13 pm

DOGEUSD

ETHUSD

PEPEUSD

SHIBUSD

Glauber Contessoto, known as the 'Dogecoin Millionaire,' has invested $100,000 in the Ethereum-based meme coin Neiro (NEIRO). He believes NEIRO has the potential to replicate the success of Dogecoin and Shiba Inu due to its high market cap, strong community support, and user-friendly nature on the Ethereum blockchain.

Portfolio Pulse from Khyathi Dalal

August 07, 2024 | 2:09 pm

AAPL

AMZN

BTCUSD

INTC

META

NVDA

This week in investing, President Trump discusses a Bitcoin strategic reserve, tech stocks face another tough week, and macroeconomic data suggests a rate cut by the Federal Reserve in September. Intel's poor earnings report stands out, while the Bank of England cuts rates and the Bank of Japan raises them. The Magnificent 7 tech stocks, including Meta, Apple, Amazon, and Nvidia, continue to struggle despite mixed earnings results.

Portfolio Pulse from Gary Brode

August 07, 2024 | 2:06 pm

AMGN

Amgen Inc. (NASDAQ:AMGN) reported strong Q2 sales growth of 20% year-over-year, driven by a 26% increase in volume. Despite missing EPS expectations, the company raised its 2024 guidance. William Blair sees significant upside potential for Amgen, particularly with its pipeline assets like MariTide, Imdelltra, and rocatinlimab. Near-term challenges include upcoming biosimilar launches and market share struggles. The stock was down 4.99% at $312.80.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 2:06 pm

MLSS

Milestone Scientific has announced a strategic partnership with Axial Biologics to distribute its CompuFlo Epidural System in New Jersey, Texas, and Florida.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 2:01 pm

PRFX

PainReform announced safety data for its PRF-110 product, revealing that maximum blood levels are at 10% of the FDA safety threshold.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 2:01 pm